COMMIT: Applicability Outside of Liver Metastasis?

Cathy Eng, MD, FACP, FASCO, of Vanderbilt-Ingram Cancer Center, shares what the COMMIT study suggest about stage 4 MSI-high colon cancer, and whether this study may have potential applicability outside of liver metastasis.

—

Dr. Eng: Whenever we have a patient that is MSI-high, we are not just focused on liver metastasis. The COMMIT study, if it is a positive study, will have value because it is in combination with chemotherapy and anti-VEGF therapy versus single-agent immune checkpoint inhibition. That is what makes it unique.

It may have benefit if it is a positive study, but then we really need to think about how much is the additional benefit, because pembrolizumab by itself seems to be quite successful. But, there is very intriguing data right now with CheckMate-8HW, which we have the final results pending in regards to overall survival, looking at nivolumab-ipilimumab versus chemotherapy, but not combined with chemotherapy.

These are all different study designs, and so once again, I think it is going to be determined by the final outcomes, the response rates, the toxicities of therapy, etc.

View her continued comments.